Exscientia appoints new leaders to strengthen oncology expertise

UK-based AI-driven precision medicines company Exscientia (Nasdaq: EXAI) today announced the appointment of two technology and clinical development leaders to senior roles to significantly strengthen the impact of differentiating technology applications as well as focused oncology pipeline development.

The move comes just weeks after Exscientia announced it was reduced its workforce by around 20% to 25% as part of a series of efficiency measures through the rest of the year that are designed to streamline the company’s operations, which it expects to result in annual savings of $40 million or more beginning in 2025.

Appointed to the post of chief technology officer, John Overington will assume strategic leadership over the company’s technology solutions to further accelerate Exscientia’s AI-led drug design platform and fully realise the transformative potential of integrating AI drug design with automated experimentation. As he brings over 30 years’ experience of bioinformatics in big pharma, biotech and academia and has authored over 150 publications on the subject.